Janus kinase (Jak) is a family of non-tyrosine receptor kinases, which play a major role in cytokine signaling. Binding of cytokines (ligand) to receptor results in receptor dimerization and ultimately activates Jak-mediated phosphorylation of the receptor. Jak phosphorylates STAT (Signal Transducer and Activator of Transcription proteins) and STAT dimer carries out the transcription of genes which are critical for signal cascade involved in inflammatory and immune response. Therefore, Janus kinase is used as a target in treatment of autoimmune disorders such as rheumatoid arthritis.
Janus Kinase Inhibitor Market Drivers
Jak inhibitors are increasingly preferred for industrial research due to their critical role in immune response signaling. For instance, in June 2018, Eli Lilly and Company announced approval from the U.S. Food and Drug Administration (FDA) for OLUMIANT (baricitinib) — an oral medication for rheumatoid arthritis in adults. Approval was granted for use of baricitinib in combination with methotrexate (MTX) or other disease-modifying antirheumatic drugs (DMARDs) or as monotherapy. The drug inhibits activation of Jak1/2 (Janus kinase 1 and 2) and decreases the production of inflammatory cytokines, thereby inhibiting inflammatory response. Therefore, increasing launch of new drugs is expected to fuel the global janus kinase inhibitor market growth over the forecast period.
Psoriatic arthritis is a form of arthritis, which is characterized by red patches of skin with silvery scales. Tofacitinib is a janus kinase inhibitor, which modulates cytokines that are required for signaling of inflammatory and immune response. Inclusion of new treatment options is expected to boost the global janus kinase inhibitor market growth over the forecast period. For instance, in December 2017, Pfizer Inc. received approval from the U.S. FDA for XELJANZ (TOFACITINIB) for treatment of adult patients suffering from psoriatic arthritis (PsA).
Furthermore, key manufacturers and research organizations are focused in research and development of new janus kinase inhibitor drugs. For instance, M.D. Anderson Cancer Center, in collaboration with Incyte Corporation, conducted phase -2 clinical trials (study completed in March 2017) to check effect of ruxolitinib in controlling advanced hematological malignancies. Ruxolitinib is an inhibitor of Jak 1 and Jak2 kinases and arrests growth of transformed cells. Therefore, active research and development of new janus kinase inhibitor drugs is expected to fuel the global janus kinase inhibitor market growth over the forecast period.
Janus Kinase Inhibitor Market Regional Analysis
The Janus kinase pathway mediates intracellular signaling of over sixty cytokines. Dysregulation of cytokines causes systemic lupus erythematosus (SLE) -- an autoimmune disorder and chronic disease, which is characterized by inflammation of connective tissues such as cartilage and blood vessel lining. According to National Center for Biotechnology Information (NCBI), the highest prevalence and incidence of SLE was in recorded in North America (23.2/100 000 person) during the period August 2013- September 2016. Therefore, high prevalence of SLE is expected to boost North America janus kinase inhibitor market growth over the forecast period.
Increasing research and development projects for launch of new drugs is expected to fuel Asia Pacific janus kinase inhibitor market growth over the forecast period. For instance, Astellas Pharma Inc. — a Japan-based pharmaceutical company — conducted Phase-3 clinical trial (study completed in November 2017) of drug Peficitinib for treatment of Rheumatoid arthritis. The study was conducted to check the superiority of Peficitinib alone and in combination with disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis who did not show sufficient response to DMARDs. Peficitinib is an inhibitor of Jak 1 and Jak that inhibits Interleukin 2 dependent T cell proliferation and STAT5 phosphorylation. These factors are expected to support global janus kinase inhibitor market growth over the forecast period.
Janus Kinase Inhibitor Market Restraints
Regulatory challenges in launch of Janus kinase inhibitors is expected to hinder the market growth. For instance, in April 2017 the U.S. FDA requested Eli Lilly & Company to provide additional clinical data for the dosing of drug Olumiant to characterize safety concerns. Later in April 2018, the FDA denied company the approval for 4mg once daily dose of Olumiant due to safety concerns regarding arterial and venous thrombosis.
Janus Kinase Inhibitor Market Key Players
Some of the key players operating in the global Janus kinase inhibitor market include, Eli Lilly and Company, Astellas Pharma Inc., Pfizer Inc., Baxter International Inc., Novartis International AG, Gilead Sciences Inc., Sierra Oncology, Inc., CTI BioPharma Corp., and Incyte Corporation.
Janus Kinase Inhibitor Market Taxonomy
The global janus kinase inhibitor market is segmented on the basis of drugs, indication, distribution channel and regions.
By Distribution Channel
Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:
In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.
Coherent Market Insights desk research is based on a principle set of research techniques:
Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:
Preliminary Data Mining
The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.
Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.
Coherent Statistical model
We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:
Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.
This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:
The primary research is conducted with the ecosystem players including, but not limited to:
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.[email protected]
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.